PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices

0
120

Opportunity ID: 328319
Opportunity Number: RFA-PS-21-003
Opportunity Title: PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.943
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Additional Information on Eligibility:
Agency Code: HHS-CDC-HHSCDCERA
Agency Name: Department of Health and Human Services
Centers for Disease Control and Prevention – ERA
Posted Date: Jul 23, 2020
Last Updated Date: Jul 23, 2020
Estimated Synopsis Post Date: Dec 01, 2020
Fiscal Year: 2021
Award Ceiling: $1,040,000
Award Floor: $0
Estimated Total Program Funding: $5,200,000
Expected Number of Awards: 1
Description: The purpose of this notice of funding opportunity is to conduct implementation research to understand the selection, adherence, persistence, and switching patterns associated with the use of FDA approved PrEP formulations by men who have sex with men (MSM). Two oral medications have been approved by the FDA as PrEP medications for MSM. Both are recommended for daily use, and one is also recommended for 2-1-1 use before and after sex rather than daily. An injectable long-acting PrEP medication that is administered every 2 months is expected to become available in 2022.
Version: 1





Visit the Official Webpage For More Details on PrEP Choice: Increasing the Use of HIV Pre-exposure Prophylaxis in an Era of Choices

LEAVE A REPLY

Please enter your comment!
Please enter your name here